RxDoctor Payments Data

Muhammad Khan, MD

Cardiovascular Disease · West Plains, MONPI 1366575151

Payments from drug & device makers

$5,445in general payments, 2019–2025

Across 128 payments — averaging $42.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abiomed$684
  • Siemens Medical Solutions USA, Inc.$376
  • GE HealthCare$370
  • Canon Medical Systems USA, Inc.$343
  • Johnson & Johnson$320
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$2,29442%
  • Food & beverage$3,15158%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,445 in reported general payments places this provider in the 65th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$151,757
Medicare patients
844
Services billed
1,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban264$297,788
EntrestoSacubitril/Valsartan91$115,599
BrilintaTicagrelor93$74,352
XareltoRivaroxaban52$72,326
Valsartan125$4,462
Metoprolol Succinate314$3,373
Ranolazine ErRanolazine26$2,958
Atorvastatin Calcium293$2,694
Carvedilol285$2,562
Midodrine Hcl34$2,499
Diltiazem 24hr Er (Cd)Diltiazem Hcl65$2,433
Potassium Chloride109$1,825
ClopidogrelClopidogrel Bisulfate136$1,598
Isosorbide Mononitrate ErIsosorbide Mononitrate164$1,499
Rosuvastatin Calcium94$1,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$297,788264 claims
NovartisEntresto$47$115,59991 claims
AstraZenecaBrilinta$83$74,35293 claims
Johnson & JohnsonXarelto$320$72,32652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in West Plains

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →